{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:24:43Z","timestamp":1786933483770,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05803-x","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:04:54Z","timestamp":1786932294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profiles of two XOD and two URAT1 inhibitors in hyperuricemic patients: a real-world pharmacovigilance analysis based on the FAERS and JADER databases"],"prefix":"10.1007","author":[{"given":"Wenqing","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xucong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefen","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"1","key":"5803_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/14740338.2023.2204227","volume":"23","author":"P An","year":"2023","unstructured":"An P, Liu X, Zhang B (2023) Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports. Expert Opin Drug Saf 23(1):119\u2013128","journal-title":"Expert Opin Drug Saf"},{"key":"5803_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-024-08180-9","author":"KM Asghari","year":"2024","unstructured":"Asghari KM, Zahmatyar M, Seyedi F, Motamedi A, Zolfi M, Alamdary SJ, Fazlollahi A, Shamekh A, Mousavi SE, Nejadghaderi SA et al (2024) Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. BMC Musculoskelet Disord. https:\/\/doi.org\/10.1186\/s12891-024-08180-9","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"5803_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18(6):427\u2013436","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"5803_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/009286151004400404","volume":"44","author":"W Bunchuailua","year":"2010","unstructured":"Bunchuailua W, Zuckerman IH, Kulsomboon V, Suwankesawong W, Singhasivanon P, Kaewkungwal J (2010) Detection of adverse drug reaction signals in the Thai FDA database: comparison between reporting odds ratio and Bayesian confidence propagation neural network methods. Drug Inf J 44(4):393\u2013403","journal-title":"Drug Inf J"},{"key":"5803_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1739631","author":"H Chen","year":"2026","unstructured":"Chen H, Jiang S, Wang J, Zhang A, Zhu L (2026) Hepatobiliary disorders associated with TNF-\u03b1 inhibitors: a pharmacovigilance analysis of FAERS and JADER. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1739631","journal-title":"Front Immunol"},{"key":"5803_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/TCRM.S424598","volume":"19","author":"C Dewi","year":"2023","unstructured":"Dewi C, Puspita F, Puspitasari IM, Zakiyah N (2023) Hepatic safety of febuxostat and allopurinol for gout patients: a systematic review of randomized controlled trial. Ther Clin Risk Manag 19:731\u2013743","journal-title":"Ther Clin Risk Manag"},{"key":"5803_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64654","author":"KM Dillman","year":"2024","unstructured":"Dillman KM, Hawkins AM, Ragland AR, Wester GC, Greene DR, Varrassi G, Moore P, Behara R, Ahmadzadeh S, Siddaiah H et al (2024) Allopurinol: clinical considerations in the development and treatment of Stevens-Johnson syndrome, toxic epidermal necrolysis, and other associated drug reactions. Cureus. https:\/\/doi.org\/10.7759\/cureus.64654","journal-title":"Cureus"},{"key":"5803_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01916-y","author":"L Du","year":"2024","unstructured":"Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, Pang Y, Zhang C, Zhong Z, Gao J (2024) Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-024-01916-y","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"5803_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"S1","key":"5803_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10157-019-01831-5","volume":"24","author":"T Hosoya","year":"2019","unstructured":"Hosoya T, Fushimi M, Okui D, Sasaki T, Ohashi T (2019) Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. Clin Exp Nephrol 24(S1):80\u201391","journal-title":"Clin Exp Nephrol"},{"issue":"S1","key":"5803_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10157-019-01802-w","volume":"24","author":"T Hosoya","year":"2019","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T (2019) Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clin Exp Nephrol 24(S1):44\u201352","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"5803_CR12","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/14656566.2021.1918102","volume":"22","author":"T Ishikawa","year":"2021","unstructured":"Ishikawa T, Takahashi T, Taniguchi T, Hosoya T (2021) Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother 22(11):1397\u20131406","journal-title":"Expert Opin Pharmacother"},{"issue":"44","key":"5803_CR13","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1093\/eurheartj\/ehab619","volume":"42","author":"EH Kang","year":"2021","unstructured":"Kang EH, Park EH, Shin A, Song JS, Kim SC (2021) Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. Eur Heart J 42(44):4578\u20134588","journal-title":"Eur Heart J"},{"issue":"36","key":"5803_CR14","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.2174\/0929867331666230809143758","volume":"31","author":"ID Karantas","year":"2024","unstructured":"Karantas ID, Miliotou AN, Siafaka PI (2024) An updated review for hyperuricemia and gout management; special focus on the available drug delivery systems and clinical trials. Curr Med Chem 31(36):5856\u20135883","journal-title":"Curr Med Chem"},{"issue":"3","key":"5803_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1253\/circrep.CR-24-0178","volume":"7","author":"K Kario","year":"2025","unstructured":"Kario K, Akari S, Kanegae H (2025) Cardiovascular events during treatment with xanthine oxidoreductase inhibitors in patients with gout and hyperuricemia in Japan - a JMDC claims database study -. Circulation Reports 7(3):183\u2013190","journal-title":"Circulation Reports"},{"issue":"10","key":"5803_CR16","doi-asserted-by":"publisher","first-page":"1180.1181","DOI":"10.3899\/jrheum.220147","volume":"49","author":"T Kawada","year":"2022","unstructured":"Kawada T (2022) Febuxostat use and safety in patients with hyperuricemia. J Rheumatol 49(10):1180.1181-1180","journal-title":"J Rheumatol"},{"issue":"6","key":"5803_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.37349\/emd.2024.00077","volume":"2","author":"RT Keenan","year":"2024","unstructured":"Keenan RT, Shen Z, Yan S, Yeh L-T, Pillinger MH (2024) How URAT1 inhibitors can shape the future of chronic gout treatment: a narrative review of uricosurics past and present. Exploration of Musculoskeletal Diseases 2(6):529\u2013554","journal-title":"Exploration of Musculoskeletal Diseases"},{"issue":"8","key":"5803_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41584-024-01137-1","volume":"20","author":"MP Leask","year":"2024","unstructured":"Leask MP, Cri\u0219an TO, Ji A, Matsuo H, K\u00f6ttgen A, Merriman TR (2024) The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies. Nat Rev Rheumatol 20(8):510\u2013523","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"5803_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10067-022-06356-z","volume":"42","author":"Y-J Li","year":"2022","unstructured":"Li Y-J, Chen L-R, Yang Z-L, Wang P, Jiang F-F, Guo Y, Qian K, Yang M, Yin S-J, He G-H (2022) Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis. Clin Rheumatol 42(1):215\u2013224","journal-title":"Clin Rheumatol"},{"key":"5803_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1485190","author":"Q Liu","year":"2024","unstructured":"Liu Q, Cui Z, Deng C, Yang C, Shi T (2024) A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1485190","journal-title":"Front Pharmacol"},{"issue":"10264","key":"5803_CR21","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R et al (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. The Lancet 396(10264):1745\u20131757","journal-title":"The Lancet"},{"key":"5803_CR22","doi-asserted-by":"crossref","unstructured":"Mao Z, Huang Y, Zhu X, Zheng P, Wang L, Zhang F, Liu W, Liu H, Liao W, Zhou L (2026) Adverse events associated with tezepelumab: a safety analysis of clinical trials and a pharmacovigilance system.\u00a0Expert Opin Drug Saf\u00a025(2):291\u2013300","DOI":"10.1080\/14740338.2024.2416921"},{"key":"5803_CR23","doi-asserted-by":"publisher","DOI":"10.34172\/jre.2025.25184","author":"H Mardanparvar","year":"2025","unstructured":"Mardanparvar H (2025) Febuxostat versus allopurinol for renoprotection; a mini-review on recent concepts. J Ren Endocrinol. https:\/\/doi.org\/10.34172\/jre.2025.25184","journal-title":"J Ren Endocrinol"},{"key":"5803_CR24","doi-asserted-by":"crossref","unstructured":"Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M\u00a0(2015) Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.\u00a0Drug Des Dev Ther\u00a09:3031\u20133041","DOI":"10.2147\/DDDT.S81998"},{"key":"5803_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241260211","author":"M Ouyang","year":"2024","unstructured":"Ouyang M, Zou S, Cheng Q, Shi X, Zhao Y, Sun M (2024) Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System. Ther Adv Drug Saf. https:\/\/doi.org\/10.1177\/20420986241260211","journal-title":"Ther Adv Drug Saf"},{"issue":"6","key":"5803_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/14656566.2023.2197591","volume":"24","author":"F Piani","year":"2023","unstructured":"Piani F, Agnoletti D, Borghi C (2023) Advances in pharmacotherapies for hyperuricemia. Expert Opin Pharmacother 24(6):737\u2013745","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"5803_CR27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/art.43215","volume":"77","author":"R Poulsen","year":"2025","unstructured":"Poulsen R, Dalbeth N (2025) Gout and NLRP3 inflammasome biology. Arthritis Rheumatol 77(10):1317\u20131326","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"5803_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41584-023-01006-3","volume":"19","author":"N Schlesinger","year":"2023","unstructured":"Schlesinger N, P\u00e9rez-Ruiz F, Liot\u00e9 F (2023) Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol 19(10):640\u2013649","journal-title":"Nat Rev Rheumatol"},{"key":"5803_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105189","author":"M Sekine","year":"2023","unstructured":"Sekine M, Okamoto K, Pai EF, Nagata K, Ichida K, Hille R, Nishino T (2023) Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase. J Biol Chem. https:\/\/doi.org\/10.1016\/j.jbc.2023.105189","journal-title":"J Biol Chem"},{"issue":"1","key":"5803_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"5803_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11906-024-01295-3","volume":"26","author":"R Vareldzis","year":"2024","unstructured":"Vareldzis R, Perez A, Reisin E (2024) Hyperuricemia: an intriguing connection to metabolic syndrome, diabetes, kidney disease, and hypertension. Curr Hypertens Rep 26(6):237\u2013245","journal-title":"Curr Hypertens Rep"},{"key":"5803_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.tifs.2023.06.021","volume":"138","author":"J Wu","year":"2023","unstructured":"Wu J, Alhamoud Y, Lv S, Feng F, Wang J (2023) Beneficial properties and mechanisms of natural phytochemicals to combat and prevent hyperuricemia and gout. Trends Food Sci Technol 138:355\u2013369","journal-title":"Trends Food Sci Technol"},{"key":"5803_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14862","author":"Z Xiao","year":"2024","unstructured":"Xiao Z, Cao J, Wu S, Zhou T, Li C, Duan J, Yang Z, Xu F (2024) Spectrum of psychiatric adverse reactions to cyclin\u2010dependent kinases 4\/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system. CNS Neurosci Ther. https:\/\/doi.org\/10.1111\/cns.14862","journal-title":"CNS Neurosci Ther"},{"key":"5803_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050450","author":"H Yanai","year":"2024","unstructured":"Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H (2024) A possible therapeutic application of the selective inhibitor of urate transporter 1, dotinurad, for metabolic syndrome, chronic kidney disease, and cardiovascular disease. Cells. https:\/\/doi.org\/10.3390\/cells13050450","journal-title":"Cells"},{"key":"5803_CR35","doi-asserted-by":"crossref","unstructured":"Ye X, Wu J, Tang K, Li W, Xiong C, Zhuo L\u00a0(2019) Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis:\u00a0two case report. Medicine\u00a098(15):e15214","DOI":"10.1097\/MD.0000000000015214"},{"issue":"13","key":"5803_CR36","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.12998\/wjcc.v7.i13.1717","volume":"7","author":"M-Y Zhang","year":"2019","unstructured":"Zhang M-Y, Niu J-Q, Wen X-Y, Jin Q-L (2019) Liver failure associated with benzbromarone: a case report and review of the literature. World J Clin Cases 7(13):1717\u20131725","journal-title":"World J Clin Cases"},{"key":"5803_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107381","author":"F Zheng","year":"2024","unstructured":"Zheng F, Mai S, Cen X, Zhao P, Ye W, Ke J, Lin S, Hu H, Guo Z, Zhang S et al (2024) Discovery of digallic acid as XOD\/URAT1 dual target inhibitor for the treatment of hyperuricemia. Bioorg Chem. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107381","journal-title":"Bioorg Chem"},{"key":"5803_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1392914","author":"S Zou","year":"2024","unstructured":"Zou S, Ouyang M, Zhao Y, Cheng Q, Shi X, Sun M (2024) A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1392914","journal-title":"Front Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05803-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:04:57Z","timestamp":1786932297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05803-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":38,"alternative-id":["5803"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05803-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not utilize individual-level data. Therefore, no new ethical approval from an ethics review committee was required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}